

# Cancer Growth Inhibitors Market & Clinical Pipeline Analysis

<https://marketpublishers.com/r/C3F2301A394EN.html>

Date: April 2015

Pages: 1000

Price: US\$ 2,400.00 (Single User License)

ID: C3F2301A394EN

## Abstracts

**Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.**

Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are entering in global market. Their rate of market introduction is expected to increase in coming years due to technological advancements and increased funding. Consequently, market introduction of these cancer growth inhibitors is expected to offer severe competition to existing cancer therapeutics in global market.

Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy.

In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.

Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.

Cancer Growth Inhibitors Covered in Report:

Cancer Tyrosine Kinase

Proteasome Inhibitors

MTOR Protein Inhibitors

Histone Deacetylase Inhibitors (HDAC inhibitors)

PI3k

“Cancer Growth Inhibitors Market & Clinical Pipeline Analysis” Report Highlight:

Introduction & Classification of Cancer Growth Inhibitors

Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase

Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs

Markets Cancer Growth Inhibitors: 48 Drugs

Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs

HDAC Inhibitors Clinical Pipeline: 65 Drugs

MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs

PI3k Clinical Pipeline: 89 Drugs

Proteasome Inhibitors Clinical Pipeline: 19 Drugs

Global Cancer Growth Inhibitors Market Future Prospects

## Contents

### **1. INTRODUCTION TO CANCER GROWTH INHIBITORS**

### **2. CLASSIFICATION OF CANCER GROWTH INHIBITORS**

### **3. CANCER GROWTH INHIBITORS MECHANISM**

### **4. GLOBAL CANCER GROWTH INHIBITORS MARKET OVERVIEW**

#### 4.1 Current Market Scenario

#### 4.2 Cancer Growth Inhibitors Clinical Pipeline Overview

### **5. GLOBAL CANCER GROWTH INHIBITORS MARKET DYNAMICS**

#### 5.1 Favorable Market Parameters

#### 5.2 Commercialization Challenges

### **6. GLOBAL CANCER GROWTH INHIBITORS MARKET FUTURE PROSPECTS**

### **7. CANCER TYROSINE KINASE CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE**

#### 7.1 Unknown

#### 7.2 Research

#### 7.3 Preclinical

#### 7.4 Clinical

#### 7.5 Phase-I

#### 7.6 Phase-I/II

#### 7.7 Phase-II

#### 7.8 Phase-II/III

#### 7.9 Phase-III

#### 7.10 Preregistration

#### 7.11 Registered

### **8. MARKETED CANCER TYROSINE KINASE CLINICAL INSIGHT**

### **9. HDAC INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE**

- 9.1 Research
- 9.2 Preclinical
- 9.3 Phase-I
- 9.4 Phase-I/II
- 9.5 Phase-II
- 9.6 Phase-III
- 9.7 Registered

## **10. MARKETED HDAC INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION**

## **11. MTOR PROTEIN INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE**

- 11.1 Research
- 11.2 Preclinical
- 11.3 Clinical
- 11.4 Phase-I
- 11.5 Phase-I/II
- 11.6 Phase-II
- 11.7 Phase-III
- 11.8 Preregistration
- 11.9 Registered

## **12. MARKETED MTOR PROTEIN INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION**

## **13. PI3K INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE**

- 13.1 Research
- 13.2 Preclinical
- 13.3 Phase-I
- 13.4 Phase-I/II
- 13.5 Phase-II
- 13.6 Phase-II/III
- 13.7 Phase-III

## **14. MARKETED PI3K INHIBITORS CLINICAL INSIGHT BY COMPANY &**

## **INDICATION**

### **15. PROTEASOME INHIBITORS CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE**

- 15.1 Research
- 15.2 Preclinical
- 15.3 Phase-I
- 15.4 Phase-I/II
- 15.5 Phase-II
- 15.6 Phase-III

### **16. MARKETED PROTEASOME INHIBITORS CLINICAL INSIGHT BY COMPANY & INDICATION**

### **17. COMPETITIVE LANDSCAPE**

- 17.1 Advaxis
- 17.2 Amgen
- 17.3 AstraZeneca
- 17.4 Bristol Mayer Squibb
- 17.5 Celldex Therapeutics
- 17.6 Eli Lilly
- 17.7 GalaxoSmithKline
- 17.8 Genetech
- 17.9 ImmunoCellular Therapeutics
- 17.10 ImmunoGen
- 17.11 Merck
- 17.12 Novartis
- 17.13 Pfizer
- 17.14 Roche
- 17.15 Sanofi
- 17.16 Teva

## List Of Figures

### LIST OF FIGURES

- Figure 1-1: Benefits of Cancer Growth Inhibitors
- Figure 1-2: Functions of Cancer Growth Inhibitors
- Figure 1-3: Improvement Required for Cancer Growth Inhibitor
- Figure 2-1: Cancer Growth Inhibitors Classification
- Figure 2-2: Different Cancer Growth Inhibitors on the Basis of their Targets
- Figure 3-1: Generalized Working of Cancer Growth Inhibitors
- Figure 3-2: Mechanism of Bortezomib
- Figure 3-3: Mechanism of Vismodegib
- Figure 3-4: Mechanism of Everolimus
- Figure 3-5: Mechanism of Bevacizumab
- Figure 3-6: Mechanism of Imatinib
- Figure 4-1: Cancer Growth Inhibitors Pipeline by Phase(%), 2015
- Figure 4-2: Cancer Growth Inhibitors Pipeline by Phase (Number), 2015
- Figure 4-3: Cancer Tyrosine Kinase Disease Pipeline by Phase (%), 2015
- Figure 4-4: Cancer Tyrosine Kinase Disease Pipeline by Phase (Numbers), 2015
- Figure 4-5: HDAC Pipeline by Phase (%), 2015
- Figure 4-6: HDAC Pipeline by Phase (Number), 2015
- Figure 4-7: Discontinued HDAC Pipeline by Phase (%), 2015
- Figure 4-8: Discontinued HDAC Pipeline by Phase (Number), 2015
- Figure 4-9: MTOR Protein Inhibitors Pipeline by Phase (%), 2015
- Figure 4-10: MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
- Figure 4-11: Discontinued MTOR Protein Inhibitors Pipeline by Phase (%), 2015
- Figure 4-12: Discontinued MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
- Figure 4-13: PI3K Pipeline by Phase (%), 2015
- Figure 4-14: PI3K Pipeline by Phase (Number), 2015
- Figure 4-15: Discontinued PI3K Pipeline by Phase (%), 2015
- Figure 4-16: Discontinued PI3K Pipeline by Phase (Number), 2015
- Figure 4-17: Proteasome Inhibitors Pipeline by Phase (%), 2015
- Figure 4-18: Proteasome Inhibitors Pipeline by Phase (Number), 2015
- Figure 4-19: No Development Reported Proteasome Inhibitors Pipeline by Phase (%), 2015
- Figure 4-20: No Development Reported Proteasome Inhibitors Pipeline by Phase (Number), 2015
- Figure 5-1: Global Cancer Growth Inhibitors Market Favorable Parameters
- Figure 5-2: Cancer Growth Inhibitors Market Commercialization Challenges

Figure 17-1: Advaxis Clinical Pipeline

Figure 17-2: Celldex Therapeutics Clinical Pipeline

Figure 17-3: ImmunoCellular Therapeutics Clinical Pipeline

Figure 17-4: ImmunoGen Clinical Pipeline



## I would like to order

Product name: Cancer Growth Inhibitors Market & Clinical Pipeline Analysis

Product link: <https://marketpublishers.com/r/C3F2301A394EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C3F2301A394EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970